No­vo Nordisk to dis­con­tin­ue long-act­ing in­sulin Lev­emir next year amid in­com­ing 65% price cut

In­sulin pow­er­house No­vo Nordisk will dis­con­tin­ue its long-act­ing in­sulin Lev­emir in the US next year amid an­tic­i­pat­ed sup­ply dis­rup­tions, a 65% price cut and as the com­pa­ny faces price ne­go­ti­a­tions with CMS for its oth­er in­sulins.

The Dan­ish drug­mak­er said sup­ply dis­rup­tions of Lev­emir Flex­Pen are ex­pect­ed in mid-Jan­u­ary 2024, but that the prod­uct “will be dis­con­tin­ued on April 1, 2024,” while the Lev­emir vial will be dis­con­tin­ued at the end of 2024.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER